Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.55 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | DRD1 | P21728 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533868 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL533867 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL6824608 | 0.87 | TSHR (0.46) | SMN1; SMN2SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL6824604 | 0.87 | TSHR (0.46) | SMN1; SMN2SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL2164318 | 0.85 | CYP1A2 (0.54) | SMN1; SMN2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL29385007 | 0.85 | CYP1A2 (0.54) | SMN1; SMN2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL2164321 | 0.85 | CYP1A2 (0.54) | SMN1; SMN2MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL19900104 | 0.85 | NPSR1 (0.55) | SMN1; SMN2SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL21195765 | 0.85 | NPSR1 (0.55) | SMN1; SMN2SLC22A1HTR1AADRA2ACHRM1 | |
| SCHEMBL5302952 | 0.85 | CYP1A2 (0.54) | SMN1; SMN2MEN1KMT2AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023137135-A1 | SOLID FORMS OF A BENZTHIAZOLE-PIPERAZINYL-OXAZOLE COMPOUND AND METHODS OF USE THEREOF | Hepagene Therapeutics (HK) Limited (CN) | 2023-07-20 | — | — | WO | disclosed |
| US-11339153-B2 | Compounds useful in modulating the farnesoid X receptor and methods of making and using the same | INORBIT THERAPEUTICS AB (SE) | 2022-05-24 | — | — | US | disclosed |
| EP-3833434-B1 | COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME | INORBIT THERAPEUTICS AB (SE) | 2021-12-15 | — | — | EP | disclosed |
| CN-113582807-A | Method for synthesizing 2, 6-dichlorobenzyl chloride | 江苏超跃化学有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20210309656-A1 | COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME | INORBIT THERAPEUTICS AB (SE) | 2021-10-07 | — | — | US | disclosed |
| EP-3529247-B1 | HETEROCYCLIC FXR MODULATORS | HEPAGENE THERAPEUTICS HK LTD (HK) | 2021-08-18 | — | — | EP | disclosed |
| WO-2020033382-A1 | COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME | INORBIT THERAPEUTICS AB (SE) | 2020-02-13 | — | — | WO | disclosed |
| EP-3202766-B1 | ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2019-12-25 | — | — | EP | disclosed |
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | Hepagene Therapeutics (HK) Limited (HK) | 2019-08-15 | — | — | US | disclosed |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-6124469-A | Process for preparing sulphurous 2-chloro-3-(4,5-dihydroisoxazol-3-yl)-benzoic acids | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-26 | — | — | US | disclosed |
| EP-0966452-A1 | PROCESS FOR PREPARING SULPHUROUS 2-CHLORO-3-(4,5-DIHYDROISOXAZOL-3-YL)-BENZOIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998031676-A1 | PROCESS FOR PREPARING SULPHUROUS 2-CHLORO-3-(4,5-DIHYDROISOXAZOL-3-YL)-BENZOIC ACIDS | BASF AKTIENGESELLSCHAFT (DE) | 1998-07-23 | — | — | WO | disclosed |
| US-4910221-A | Having a halogen group in position 4 of ring | BAYER AKTIENGESELLSCHAFT (DE) | 1990-03-20 | — | — | US | disclosed |
| US-4859235-A | Pesticidal α-methylsulphonyl-benzaldoximes and carbamates thereof | BAYER AKTIENGESELLSCHAFT (DE) | 1989-08-22 | — | — | US | disclosed |
| EP-0286964-A2 | Alpha-methyl-sulfonyl-benzadoxime carbamate | BAYER AG (DE) | 1988-10-19 | — | — | EP | disclosed |
| EP-0258391-A1 | USE OF HETEROCYCLIC NITROGEN-CONTAINING COMPOUNDS FOR REDUCING MOISTURE LOSS FROM PLANTS AND INCREASING CROP YIELD | RHONE POULENC NEDERLAND B.V. (NL) | 1988-03-09 | — | — | EP | disclosed |
| WO-1987004321-A2 | USE OF HETEROCYCLIC NITROGEN-CONTAINING COMPOUNDS FOR REDUCING MOISTURE LOSS FROM PLANTS AND INCREASING CROP YIELD | RHONE-POULENC NEDERLANDS B.V. (NL) | 1987-07-30 | — | — | WO | disclosed |
| EP-0208110-A1 | Fungicidal agent based on a benzaldoxime derivative | BAYER AG (DE) | 1987-01-14 | — | — | EP | disclosed |
| US-4283403-A | Substituted isoxazolines for control of plant phytopathogens | ELI LILLY AND COMPANY (US) | 1981-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248752-A1 | HETEROCYCLIC FXR MODULATORS | NR1H4, FXR1, NR1H2 | SMN1; SMN2 4879/4885SLC22A1 1678/4885HTR1A 1834/4885 |
| US-11339153-B2 | Compounds useful in modulating the farnesoid X receptor and methods of making and using the same | NR1H4, SLC10A2, FXR2 | SMN1; SMN2 3384/4885SLC22A1 193/4885HTR1A 3512/4885 |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | IDH1, IDH3A, IDH3B | SMN1; SMN2 2777/4885SLC22A1 1585/4885HTR1A 3533/4885 |
| US-20210309656-A1 | COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME | NR1H4, FXR1, FXR2 | SMN1; SMN2 4870/4885SLC22A1 1605/4885HTR1A 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.